Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
August 2011
Features
Clinical and Economic Impact of Early Versus Delayed 5-Alpha Reductase Inhibitor Therapy in Men Taking Alpha Blockers for Symptomatic Benign Prostatic Hyperplasia
Patients with prostatic enlargement who had taken an alpha blocker and were then given a 5-alpha reductase inhibitor earlier rather than later had a reduced risk of clinical progression, acute urinary retention, and prostate-related surgery, as well as lower medical costs.
Eric J. Kruep, PharmD, MS; Susan L. Hogue, PharmD, MPH; Michael T. Eaddy, PharmD, PhD; and Monica D. Chandra, MPP
Meeting Highlights
2011 American Society of Clinical Oncology
Therapies for melanoma; glioblastoma; non–small-cell lung cancer; gastrointestinal, prostate, and breast cancers; myelofibrosis; and markers for
lymph-node mapping and antibody response
Walter Alexander
Book Review
An Overview of the Current Prescription Benefits Landscape
Pharmacy Benefits: Plan Design and Management by F. Randy Vogenberg, PhD, RPh
Reviewed by Joseph E. Biskupiak, PhD, MBA
Continuing Education Credit
Medication Management of Atrial Fibrillation
Emerging Therapies for Rhythm Control and Stroke Prevention
Non-drug strategies, new antiarrhythmic agents, and anticoagulants all help to
reduce the risk of stroke and provide rhythm control. However, clinicians who
prescribe these therapies must consider the patient’s other illnesses, manage drug interactions, minimize drug toxicity, adjust doses for renal impairment, and provide counseling on the risks of potential adverse effects.
Emily Knapp, PharmD, MBA; and Kristin Watson, PharmD, BCPS
Departments
Medication Errors
Keeping Patients Safe From Methadone Overdoses
Methadone must be administered with great caution.
Matthew Grissinger, RPh, FASCP
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Medullary thyroid cancer, restless legs syndrome, and preventing kidney transplant rejection
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia
Lurasidone HCl (Latuda), an oral, atypical antipsychotic agent for schizophrenia
Martin P. Cruz, PharmD, CGP, BCPP
